Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects

Authors: M Vourvahis, R Wong, NM Ndongo, M O'Gorman, M Tawadrous

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Lersivirine (LRV) is a next-generation NNRTI currently under investigation in two Phase IIb studies at doses of 500 - 1000 mg QD. In vitro analyses suggest that LRV is a weak Ikr and CA2+ channel blocker. However, dose-ranging Phase I studies have not shown prolongation of QTc interval to date. This study was performed to investigate the effect of a supratherapeutic dose of LRV on QTc interval in healthy subjects, relative to matched placebo and active control. …
Metadata
Title
No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
Authors
M Vourvahis
R Wong
NM Ndongo
M O'Gorman
M Tawadrous
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P225

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Poster presentation

Nutritional status in HIV-infected patients using Changi's mini nutritional assessment

Poster presentation

High prevalence of genotype G in HIV co-infected patients compared with HBV monoinfected patients in México

Poster presentation

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

Oral presentation

O112. International perspectives on adherence and resistance to HIV antiretroviral therapy

Poster presentation

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting

Poster presentation

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits